IL131495A0 - Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds - Google Patents

Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds

Info

Publication number
IL131495A0
IL131495A0 IL13149598A IL13149598A IL131495A0 IL 131495 A0 IL131495 A0 IL 131495A0 IL 13149598 A IL13149598 A IL 13149598A IL 13149598 A IL13149598 A IL 13149598A IL 131495 A0 IL131495 A0 IL 131495A0
Authority
IL
Israel
Prior art keywords
hydroxamic acid
acid compounds
divalent aryl
sulfonyl divalent
sulfonyl
Prior art date
Application number
IL13149598A
Other languages
English (en)
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of IL131495A0 publication Critical patent/IL131495A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL13149598A 1997-03-04 1998-03-04 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds IL131495A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3518297P 1997-03-04 1997-03-04
PCT/US1998/004300 WO1998038859A1 (en) 1997-03-04 1998-03-04 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds

Publications (1)

Publication Number Publication Date
IL131495A0 true IL131495A0 (en) 2001-01-28

Family

ID=21881145

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13149598A IL131495A0 (en) 1997-03-04 1998-03-04 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
IL13149398A IL131493A (en) 1997-03-04 1998-03-04 Aromatic compounds of the hydroxamic sulfonyl alpha-deroxamic acid and their use in the preparation of drugs for the treatment of a condition associated with pathological activity of the metalloprotease matrix
IL13149498A IL131494A (en) 1997-03-04 1998-03-04 N-hydroxy 4-sulfonyl butanamide compounds and their use to prepare medicaments for treating conditions associated with matrix metalloproteinase activity

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL13149398A IL131493A (en) 1997-03-04 1998-03-04 Aromatic compounds of the hydroxamic sulfonyl alpha-deroxamic acid and their use in the preparation of drugs for the treatment of a condition associated with pathological activity of the metalloprotease matrix
IL13149498A IL131494A (en) 1997-03-04 1998-03-04 N-hydroxy 4-sulfonyl butanamide compounds and their use to prepare medicaments for treating conditions associated with matrix metalloproteinase activity

Country Status (19)

Country Link
US (3) US6380258B2 (enExample)
EP (4) EP0973392B1 (enExample)
JP (4) JP2002513407A (enExample)
KR (3) KR20000075954A (enExample)
CN (3) CN1254337A (enExample)
AT (1) ATE254599T1 (enExample)
AU (2) AU750130B2 (enExample)
BR (2) BR9808166A (enExample)
CA (4) CA2283145A1 (enExample)
DE (1) DE69819878T2 (enExample)
DK (1) DK0973392T3 (enExample)
EA (1) EA199900792A1 (enExample)
ES (2) ES2209122T3 (enExample)
IL (3) IL131495A0 (enExample)
NO (1) NO315647B1 (enExample)
NZ (1) NZ337326A (enExample)
PL (1) PL335732A1 (enExample)
PT (1) PT973392E (enExample)
WO (1) WO1998038859A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
US6696449B2 (en) * 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
ES2209122T3 (es) 1997-03-04 2004-06-16 Pharmacia Corporation Compuestos de acido sulfonil alfa-hidroxi hidroxamico aromatico.
HUP0100812A3 (en) * 1997-11-21 2002-11-28 Upjohn Co Alpha-hydroxy, -amino and -fluoro derivatives of betha-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors
WO2000037433A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
AU3312100A (en) 1999-03-22 2000-10-09 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
BR0011291A (pt) * 1999-05-12 2002-05-14 Searle & Co Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
EP2292593A3 (en) * 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
JP4606027B2 (ja) * 2002-04-03 2011-01-05 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのピペラジン結合を有するカルバミン酸化合物
WO2003091247A2 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0226855D0 (en) * 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
DE602005017879D1 (de) * 2004-03-22 2010-01-07 Southern Res Inst Nichtpeptidinhibitoren von matrixmetalloproteinasen
US20050250789A1 (en) * 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
CA2567443A1 (en) * 2004-06-01 2006-01-12 The Scripps Research Institute Proteomic analysis
US20050277897A1 (en) * 2004-06-14 2005-12-15 Ghannoum Ziad R Handpiece tip
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
WO2010050461A1 (ja) * 2008-10-27 2010-05-06 田辺三菱製薬株式会社 新規アミド誘導体およびその医薬としての用途
CA2777108A1 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
JP5913310B2 (ja) 2010-07-22 2016-04-27 ザフゲン，インコーポレイテッド 三環式化合物ならびにその作製および使用方法
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
CN104892457B (zh) * 2011-07-25 2017-07-28 中国医学科学院医药生物技术研究所 一种异羟肟酸类衍生物、其药物组合物、制备方法及用途
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
CN104169268A (zh) 2012-01-18 2014-11-26 扎夫根股份有限公司 三环砜化合物及其制备和使用方法
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
JP2015536981A (ja) 2012-11-05 2015-12-24 ザフゲン，インコーポレイテッド 三環式化合物ならびにその製造および使用方法
CA2890344A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
CN104769090B (zh) * 2012-11-09 2018-01-02 荷兰联合利华有限公司 用于处理基底的组合物和方法
WO2015175813A1 (en) 2014-05-14 2015-11-19 The Regents Of The University Of Colorado, A Body Corporate Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
JP2019513703A (ja) * 2016-03-17 2019-05-30 ゼニオプロ ゲーエムベーハー ＮｏｔｃｈシグナリングのエンハンサーならびにＮｏｔｃｈのアップレギュレーションにより治療可能ながんおよび悪性腫瘍の治療におけるその使用
WO2020006384A1 (en) 2018-06-29 2020-01-02 Loyola University Of Chicago Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy
CN111217722B (zh) * 2020-03-06 2024-01-02 华东理工大学 偶氮芳基脲类衍生物及其制备方法和应用
CN116102391B (zh) * 2023-01-06 2025-01-28 湖大粤港澳大湾区创新研究院(广州增城) 二硫转移试剂及其合成与应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148801A (en) * 1978-07-03 1979-04-10 American Home Products Corporation 3-[(Chlorophenylsulfonyl)methyl]-1,2,4-oxadiazole-5-carboxylic acid derivatives
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
GB2212153B (en) 1987-11-16 1992-01-15 Squibb & Sons Inc Phenyl hydroxamic acids
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5527945A (en) * 1989-02-10 1996-06-18 Basf Aktiengesellschaft Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom
ATE159938T1 (de) * 1990-12-17 1997-11-15 Sankyo Co Pyrazolderivate mit herbizider wirkung, deren herstellung und verwendung
JP3348725B2 (ja) * 1992-04-07 2002-11-20 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤
US5376664A (en) 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
GB9307956D0 (en) 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
GB9323165D0 (en) 1993-11-10 1994-01-05 Chiros Ltd Compounds
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
CN1193978A (zh) 1994-10-05 1998-09-23 奇罗斯恩有限公司 肽基化合物和它们作为金属蛋白酶抑制剂的医疗用途
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
AU725831C (en) 1995-12-08 2002-10-17 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
AU1529897A (en) * 1996-01-02 1997-07-28 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
EP0994104A4 (en) 1996-06-27 2001-09-12 Ono Pharmaceutical Co ARYL SULFIDE, SULFOXIDE AND SULPHONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM AS AN ACTIVE INGREDIENT
EP0968182B1 (en) * 1996-08-07 2004-05-06 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
KR20000048639A (ko) * 1996-09-27 2000-07-25 로렌스 티. 마이젠헬더 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산
EP0853255B1 (en) * 1997-01-13 2001-09-05 Fuji Photo Film Co., Ltd. Heat developable color photosensitive material
CA2279863A1 (en) * 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
UA58543C2 (uk) * 1997-02-27 2003-08-15 Амерікан Ціанамід Компані N-гідрокси-2-(алкіл-, арил-, або гетероарилсульфаніл, -сульфініл або -сульфоніл)-3-заміщені алкіл-, арил- або гетероариламіди як інгібітори матричних металопротеїназ
ES2209122T3 (es) 1997-03-04 2004-06-16 Pharmacia Corporation Compuestos de acido sulfonil alfa-hidroxi hidroxamico aromatico.
US20010014688A1 (en) * 1997-11-14 2001-08-16 Thomas E. Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor

Also Published As

Publication number Publication date
ES2209122T3 (es) 2004-06-16
CN1105114C (zh) 2003-04-09
KR20000075946A (ko) 2000-12-26
EP0984959A1 (en) 2000-03-15
NO994252L (no) 1999-09-02
CA2283145A1 (en) 1998-09-11
BR9808166A (pt) 2000-05-16
KR20000075954A (ko) 2000-12-26
EP0984959A4 (en) 2001-05-02
US20020103239A1 (en) 2002-08-01
EP0984959B1 (en) 2003-09-24
ES2206903T3 (es) 2004-05-16
CN1254337A (zh) 2000-05-24
EP0973392A1 (en) 2000-01-26
EP0973392A4 (en) 2001-05-02
IL131494A (en) 2005-06-19
AU6542498A (en) 1998-09-22
NO994252D0 (no) 1999-09-02
AU750303B2 (en) 2002-07-18
IL131494A0 (en) 2001-01-28
ATE254599T1 (de) 2003-12-15
WO1998038859A1 (en) 1998-09-11
EP0983258A4 (en) 2001-01-17
JP2002513407A (ja) 2002-05-08
HK1027806A1 (en) 2001-01-23
EP0983257A1 (en) 2000-03-08
JP2002515901A (ja) 2002-05-28
EP0983258A1 (en) 2000-03-08
NO315647B1 (no) 2003-10-06
EA199900792A1 (ru) 2000-04-24
BR9808214A (pt) 2000-05-16
DK0973392T3 (da) 2004-03-29
AU6686598A (en) 1998-09-22
JP2002515900A (ja) 2002-05-28
PL335732A1 (en) 2000-05-08
US6380258B2 (en) 2002-04-30
US20040097487A1 (en) 2004-05-20
CA2283275A1 (en) 1998-09-11
DE69819878T2 (de) 2004-04-22
DE69819878D1 (de) 2003-12-24
NZ337326A (en) 2001-05-25
AU750130B2 (en) 2002-07-11
IL131493A (en) 2004-05-12
PT973392E (pt) 2004-04-30
AU6447898A (en) 1998-09-22
CA2282318A1 (en) 1998-09-11
US6656954B2 (en) 2003-12-02
KR20000075955A (ko) 2000-12-26
JP2001518081A (ja) 2001-10-09
US20010020021A1 (en) 2001-09-06
CN1253559A (zh) 2000-05-17
EP0983257A4 (en) 2001-05-02
IL131493A0 (en) 2001-01-28
AU737329B2 (en) 2001-08-16
CN1253474A (zh) 2000-05-17
EP0973392B1 (en) 2003-11-19
CA2283272A1 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
IL131495A0 (en) Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
DE69827940D1 (en) Thiarylsulfonamid-hydroxamsäurederivate
WO2001085680A3 (en) Sulfonyl aryl or heteroaryl hydroxamic acid compounds
AP2001002240A0 (en) Sufamato hydroxamic acid metalloprotease inhibitor.
NZ515197A (en) Hydroxamic acid derivatives useful as matrix metalloprotease inhibitors
IL135921A (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
DE69305642D1 (de) Injizierbares Arzneimittel und Satz, die Omoprazol oder verwandte Verbindungenenthalten
GEP20022678B (en) Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, their Pharmaceutical compositions and methods for Treatment
CA2268484A1 (en) Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
NZ331327A (en) Serine protease inhibitors having an acylguanidine side chain
MX9706380A (es) Guanidinas de acidos alquenil-carboxilicos sustituidos con fenilo, procedimientos para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como un medicamento que las contiene.
WO2003007954A3 (en) Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
NZ331484A (en) Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases
EP0342587A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
MY141460A (en) Aromatic sulfone hydroxamic acid metalloprotease inhibitor
SU1166473A1 (ru) ДИТИОАЦЕТИЛГИДРАЗОН α -КАМФОРХИНОНА, ПРОЯВЛЯЮЩИЙ ПРОТИВОГИПОКСИЧЕСКУЮ АКТИВНОСТЬ